Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

The price predictions on this page represent Cryptonews' market analysis based on available data and trends, but should not be considered as financial or investment advice. Cryptocurrency markets are ...